Overview

A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne

Status:
Completed
Trial end date:
2010-11-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess safety and efficacy of a new foam formulation of tazarotene in subjects with acne vulgaris.
Phase:
Phase 3
Details
Lead Sponsor:
Stiefel, a GSK Company
Collaborator:
GlaxoSmithKline
Treatments:
Nicotinic Acids
Tazarotene